title: Biphasic changes in left ventricular end-diastolic pressure during dynamic exercise in patients with nonobstructive hypertrophic cardiomyopathy.
abstract: OBJECTIVE
  The aim of this study was to clarify the serial changes in left ventricular (LV) end-diastolic pressure (LVEDP) during dynamic exercise in patients with hypertrophic cardiomyopathy (HCM).
  
  
  BACKGROUND
  Although HCM is characterized by impaired resting LV diastolic function, serial changes in LVEDP during exercise have not been characterized.
  
  
  METHODS
  We simultaneously measured LV pressure and LV dimensions during symptom-limited supine bicycle exercise in 5 healthy individuals and 20 patients with HCM. Exercise thallium-201 scintigraphic studies were also performed.
  
  
  RESULTS
  The LVEDP (baseline: 12 +/- 5 mm Hg) progressively increased to a maximum value at peak exercise (28 +/- 8 mm Hg) in 11 patients with HCM (group I). In the remaining nine patients with HCM (group II), changes in LVEDP during exercise were biphasic, with an initial progressive increase and a subsequent gradual decline up to peak exercise (14 +/- 4 mm Hg at baseline, 27 +/- 5 mm Hg at the critical heart rate, 16 +/- 3 mm Hg at peak exercise). Exercise-induced changes in LV dimensions and LV peak systolic pressures were similar in both groups. However, the maximum first derivative of LV pressure was greater and the LV pressure half-time was shorter in group II than in group I at a similar peak exercise heart rate. The biphasic changes in LVEDP disappeared by pretreatment with propranolol. The LV hypertrophy scores were higher in group I than in group II. Exercise thallium-201 images showed more severe perfusion defects in group I than in group II patients.
  
  
  CONCLUSIONS
  The biphasic changes in LVEDP seen during exercise may be related to improved coronary microcirculation in response to beta-adrenergic stimulation in patients with mild to moderate HCM.
authors.affiliation: Cardiovascular Division, Nagoya University, Graduate School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takeichi
authors.forename: M
authors.initials: M
authors.lastname: Yokota
authors.forename: M
authors.initials: M
authors.lastname: Iwase
authors.forename: H
authors.initials: H
authors.lastname: Izawa
authors.forename: T
authors.initials: T
authors.lastname: Nishizawa
authors.forename: R
authors.initials: R
authors.lastname: Ishiki
authors.forename: F
authors.initials: F
authors.lastname: Somura
authors.forename: K
authors.initials: K
authors.lastname: Nagata
authors.forename: S
authors.initials: S
authors.lastname: Isobe
authors.forename: A
authors.initials: A
authors.lastname: Noda
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure; D002312:Cardiomyopathy, Hypertrophic / Q000097:blood / Q000000981:diagnostic imaging / Q000503:physiopathology*; D002395:Catecholamines / Q000097:blood; D003971:Diastole; D004562:Electrocardiography; D015444:Exercise; D006321:Heart / Q000187:drug effects; D006339:Heart Rate; D006801:Humans; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis; D011433:Propranolol / Q000494:pharmacology; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000000981:diagnostic imaging / Q000503:physiopathology*; D017725:Ventricular Pressure
chemical_list: D002395:Catecholamines; D011433:Propranolol